Cash Jumps to $189M as AF Pivotal Study Enrolls Three Months Early
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Pulse Biosciences ended Q3 with $189.2 million in cash and marketable securities, up from $101.6 million at June 30, after raising $95.8 million in net ATM proceeds during the quarter. Total since May tops $150 million at under 6% dilution, with roughly $64 million of ATM capacity left. Revenue was $0.4 million versus $0.1 million a year ago, while GAAP net loss widened to $23.1 million from $19.4 million on higher clinical and employee spend, or 32 cents a share. The clinical story is the driver: NANOPULSE-AF pivotal enrollment finished with 169 evaluable patients in under six months, three months ahead of the original timeline, and the company plans a persistent AF IDE submission in Q4 2026. Next up: 12-month follow-up data on 100 EU feasibility patients in Q1 2027 and a CE Mark submission targeting approval in Q4 2027.
At the time of this announcement, PLSE was trading at $53.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $12.56 to $58.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.